Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)

Phase 4

Completed

Conditions: Chronic Rhinosinusitis With Nasal Polyps

Interventions: Drug: Dupilumab SAR231893

First Posted Date: 2021-09-17

Last Posted Date: 2024-01-22

Lead Sponsor: Sanofi

Target Recruit Count: 25

Registration Number: NCT05049122

Locations: 🇯🇵
Investigational site JAPAN, Japan, Japan

Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A

Phase 1

Completed

Conditions: Hemophilia A

Interventions: Drug: Efanesoctocog alfa
Drug: Octocog alfa
Drug: Rurioctocog alfa pegol

First Posted Date: 2021-09-13

Last Posted Date: 2023-08-03

Lead Sponsor: Sanofi

Target Recruit Count: 13

Registration Number: NCT05042440

Locations: 🇧🇬
Investigational Site Number :1000001, Sofia, Bulgaria

Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

Phase 2

Recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: SAR441344 IV
Drug: Placebo IV
Drug: SAR441344 SC
Drug: Placebo SC

First Posted Date: 2021-09-10

Last Posted Date: 2024-12-06

Lead Sponsor: Sanofi

Target Recruit Count: 116

Registration Number: NCT05039840

Locations: 🇺🇸
Private Practice - Dr. Ramesh C. Gupta I- Site Number : 8400008, Memphis, Tennessee, United States
🇺🇸
Tekton Research - West Gate- Site Number : 8400001, Austin, Texas, United States
🇺🇸
Precision Comprehensive Clinical Research Solutions - Colleyville- Site Number : 8400017, Colleyville, Texas, United States

and more 68 locations

Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Placebo
Drug: Rilzabrutinib

First Posted Date: 2021-08-24

Last Posted Date: 2024-06-21

Lead Sponsor: Sanofi

Target Recruit Count: 124

Registration Number: NCT05018806

Locations: 🇺🇸
Integrative Skin Care of MS/SKYCRNG Site Number : 8400011, Ridgeland, Mississippi, United States
🇵🇱
Investigational Site Number : 6160005, Gdansk, Pomorskie, Poland
🇵🇱
Investigational Site Number : 6160002, Lodz, Poland

and more 28 locations

Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors

Phase 1

Terminated

Conditions: Breast Cancer
Neoplasm Malignant
Lung Neoplasm Malignant
Gastric Cancer
Neoplasm

Interventions: Drug: SAR443216 IV
Drug: SAR443216 SC

First Posted Date: 2021-08-19

Last Posted Date: 2024-02-09

Lead Sponsor: Sanofi

Target Recruit Count: 44

Registration Number: NCT05013554

Locations: 🇺🇸
~University of Texas - MD Anderson Cancer Center Site Number : 8400002, Houston, Texas, United States
🇧🇪
Investigational Site Number : 0560002, Gent, Belgium
🇫🇷
Investigational Site Number : 2500001, Pierre Benite, France

and more 8 locations

Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)

Phase 2

Active, not recruiting

Conditions: Warm Autoimmune Hemolytic Anemia (wAIHA)

Interventions: Drug: rilzabrutinib

First Posted Date: 2021-08-12

Last Posted Date: 2024-06-24

Lead Sponsor: Sanofi

Target Recruit Count: 22

Registration Number: NCT05002777

Locations: 🇺🇸
University of Southern California_Investigational Site Number: 8400009, Los Angeles, California, United States
🇺🇸
TOI Clinical Research LLC_Santa Ana_Investigational Site Number: 8400006, Santa Ana, California, United States
🇺🇸
The Lundquist Institute_Investigational Site Number: 8400005, Torrance, California, United States

and more 24 locations

A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Insulin glargine 300 U/ml

First Posted Date: 2021-08-12

Last Posted Date: 2023-03-09

Lead Sponsor: Sanofi

Target Recruit Count: 570

Registration Number: NCT05002933

Locations: 🇨🇳
Investigational Sites, China, China

EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients

Phase 4

Active, not recruiting

Conditions: Chronic Rhinosinusitis With Nasal Polyps
Asthma

Interventions: Drug: Dupilumab
Drug: Omalizumab
Drug: Placebo

First Posted Date: 2021-08-10

Last Posted Date: 2024-08-29

Lead Sponsor: Sanofi

Target Recruit Count: 320

Registration Number: NCT04998604

Locations: 🇺🇸
Cedars Sinai Medical Center Site Number : 8400026, Los Angeles, California, United States
🇺🇸
Northwell Health Site Number : 8400044, Great Neck, New York, United States
🇺🇸
Cleveland Clinic Foundation Site Number : 8400029, Cleveland, Ohio, United States

and more 92 locations